Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03556228
Title Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors VM Oncology, LLC
Indications

malignant mesothelioma

non-Hodgkin lymphoma

acute myeloid leukemia

thymic carcinoma

melanoma

lymphoma

ovarian cancer

hepatocellular carcinoma

thymoma

prostate cancer

Advanced Solid Tumor

head and neck squamous cell carcinoma

esophageal cancer

lung squamous cell carcinoma

stomach cancer

adenoid cystic carcinoma

cervical cancer

Therapies

VMD-928

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.